Quarterly report · Q3

Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥523.5bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥178.8bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥94.5bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥28.6bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥93.0bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥27.8bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥71.7bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥21.7bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥71.7bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥21.7bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥1.54Tat 2022-12-31Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.40Tat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥469.8bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥935.9bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥935.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥204.9bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥98.4bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥59.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥39.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥94.822021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥28.72021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥94.762021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥28.692021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-12-31¥190m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.7bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥90.2bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥17.2bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥294.4bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥72.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥138.7bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥19.3bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥523.3bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥108.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 648
ItemContextValueUnit
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember2758000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-2758000000JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-JPY
Transfer from other components of equity to retained earnings ss IFRSCurrentYTDDuration-JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Share based payment transactions ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember54000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember123000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-JPY
Share based payment transactions ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember57000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember235000000JPY
Share based payment transactions ss IFRSCurrentYTDDuration235000000JPY
Total transactions with owners IFRSCurrentYTDDuration_ShareCapitalIFRSMember-JPY
Total transactions with owners IFRSCurrentYTDDuration_CapitalSurplusIFRSMember15000000JPY
Total transactions with owners IFRSCurrentYTDDuration_TreasurySharesIFRSMember-49791000000JPY
Total transactions with owners IFRSCurrentYTDDuration_RetainedEarningsIFRSMember-25165000000JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-2805000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-77747000000JPY
Total transactions with owners IFRSCurrentYTDDuration-77747000000JPY
Equity IFRSCurrentQuarterInstant_ShareCapitalIFRSMember38716000000JPY
Equity IFRSCurrentQuarterInstant_CapitalSurplusIFRSMember51937000000JPY
Equity IFRSCurrentQuarterInstant_TreasurySharesIFRSMember-56020000000JPY
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember891992000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember147085000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember1073711000000JPY
Equity IFRSCurrentQuarterInstant1073711000000JPY
Profit loss before tax IFRSPrior1YTDDuration93044000000JPY
Profit loss before tax IFRSCurrentYTDDuration92100000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration43317000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration52445000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration-JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration5377000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration-433000000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration-136000000JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSPrior1YTDDuration-373000000JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSCurrentYTDDuration482000000JPY
Interest and dividend income ope cf IFRSPrior1YTDDuration-483000000JPY
Interest and dividend income ope cf IFRSCurrentYTDDuration-991000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration1316000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration1821000000JPY
Foreign exchange loss gain ope cf IFRSPrior1YTDDuration1291000000JPY
Foreign exchange loss gain ope cf IFRSCurrentYTDDuration2009000000JPY
Loss gain on sale and retirement of fixed assets ope cf IFRSPrior1YTDDuration326000000JPY
Loss gain on sale and retirement of fixed assets ope cf IFRSCurrentYTDDuration-160000000JPY
Gain on transfer of business and other ope cf IFRSPrior1YTDDuration-JPY
Gain on transfer of business and other ope cf IFRSCurrentYTDDuration-3891000000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration-2899000000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration-13415000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-5354000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-29618000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass